First Liquid Biopsy for Neurologic Diseases

18 – 30% of cases of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease are misdiagnosed.

The FBB Biomed blood test measures newly discovered RNA biomarkers for these neurologic diseases to increase diagnostic accuracy at the time of first diagnosis. This is the world’s first liquid biopsy for neurologic diseases.

Explore Our Technology

The Challenge

Neurologic Misdiagnosis

Screening protocols for neurologic diseases – including Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), and Alzheimer’s Disease (AD) – currently rely on imprecise diagnostic methods and fail to provide a prognostic view to health outcomes.
 
Research indicates that up to a third of cases are misdiagnosed within this disease group, leading to incorrect treatment protocols and the use of wrong medications.

Our Solution

RNA Biomarkers

FBB Biomed’s newly discovered RNA biomarkers increase diagnostic accuracy at the time of screening by providing a molecular diagnostic for MS, PD, and AD.
 
FBB Biomed’s pre-clinical research has demonstrated significant potential for earlier, more accurate diagnosis of these diseases.

Our Product

NGS-based Blood Test

FBB Biomed’s proprietary reagent and bioinformatics software power our blood test based on RNA biomarkers. Our test provides neurologists with a liquid biopsy for the diagnosis of Multiple Sclerosis, Parkinson’s Disease, and Alzheimer’s Disease.

Our test runs on standard laboratory sequencing equipment and protocols. No new hardware or processes required.

Actionable Clinical Utility

Use Cases

Early Diagnosis

Is this patient suffering from neurodegeneration?

Differential Diagnosis

Which neurologic disease does this patient have?

Patient Monitoring

How effective has the prescribed therapy been so far?

From the Scientific Community

What Others Say About Us

“If we could look at biomarkers and understand who is going to progress to the most severe form of the disease, it also could change the therapies that we would offer to that patient. This is where we could have a tremendous impact on the whole course of a disease.”
Dr. Patricia Winokur, Executive DeanCarver College of Medicine, University of Iowa
Dr. Patricia Winokur, Executive Dean
“If we could identify biomarkers that are associated with a poor prognosis for COVID-19 or any other disease, then we would know – prior to that person having a poor outcome – that they were at risk for a poor outcome.”
Dr. Richard Smith, DirectorIowa Institute of Human Genetics, University of Iowa
Dr. Richard Smith, Director
“We take all the data and let the machine learning approach guide us through which genes or which transcripts or which patterns are actually important rather than putting our own bias into what we think is important.”
Dr. Henry Keen, Research ScientistIowa Institute of Human Genetics, University of Iowa
Dr. Henry Keen, Research Scientist
“FBB Biomed’s research does not look into single values of the immune status but looks at the history of the immune system and gives a complete picture of what has happened to that individual person.”
Dr. Heinz Hänel, Advisor to FBB BiomedHonorary Professor, Goethe University
Dr. Heinz Hänel, Advisor to FBB Biomed